Among them, GPR-109A can inhibit NF-kB activation and pancreatic β cell inflammation, and the increased expression of GPR-109A in renal injury models can alleviate proteinuria, stabilize glomerular basement membrane podocytes, and alleviate glomerular sclerosis and kidney inflammation (58) (Figure 2). Here, HCAR2 is linked to glomerulosclerosis.